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	 	 -	 	A	thromboembolic	event	will	be	defined	as	any	stroke,	systemic	
embolism,	or	myocardial	infarction.




	 	 -	 	Any	stroke,	systemic	embolism,	myocardial	infarction,	or	major	bleeding
	 	 -	 	Age,	gender,	height,	weight,	serum	creatinine,	and	creatinine	clearance
	 	 -	 	History	of	congestive	heart	failure,	hypertension,	diabetes	mellitus,	or	
previous	stroke,	transient	ischemic	attack,	or	cerebrovascular	accident	
as	documented	in	the	permanent	medical	record
	 	 -	 	Usage	of	concomitant	anti-platelet	therapy
	 	 -	 	Hemoglobin	if	bleeding	suspected	and	any	transfusions
	 	 -	 	Date	of	readmission	and	reason	for	readmission,	if	any
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or	personal	relationships	with	commercial	entities	that	may	have	a	direct	or	indirect	
interest	in	the	subject	matter	of	this	presentation.	
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•		Appropriateness	of	dabigatran	dosing	will	also	be	assessed	based	
on	the	patient’s	renal	function	in	accordance	with	this	product’s	FDA	
approved	dosing	recommendations.
•		Following	data	collection,	the	observed	rates	of	the	composite	
endpoint	will	be	reported	and	statistically	evaluated	using	a	2-sided	
95	percent	confidence	interval,	computed	around	the	difference	in	
observed	rates.	
